Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

Video

Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.

OND0558_Endur_Seg05_PROandQOL
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Strategic Sequencing in HER2+ Breast Cancer: Optimizing Treatment in the Third Line and Beyond
      Strategic Sequencing in HER2+ Breast Cancer: Optimizing Treatment in the Third Line and Beyond
      Patient Case Presentation: A 47-Year-Old Woman With HER2+ mBC and CNS Progression
      Patient Case Presentation: A 47-Year-Old Woman With HER2+ mBC and CNS Progression
      Outcomes and Factors for Consideration When Choosing Between CAR T Therapies
      Outcomes and Factors for Consideration When Choosing Between CAR T Therapies
      Late-Line R/R: Treatment Landscape
      Late-Line R/R: Treatment Landscape
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
      The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
      Treatment of Earlier-Stage Disease May Strengthen NMIBC-Related Survival
      Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
      Sasanlimab Combo Improves EFS “Across the Board” in BCG-Naive NMIBC
      Related Content
      Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

      AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

      Russ Conroy
      July 1st 2025
      Article

      Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

      A Sneak Peek at 2025 ASCO From the GU Perspective

      A Sneak Peek at 2025 ASCO From the GU Perspective

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
      May 15th 2025
      Podcast

      Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

      The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

      FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

      Roman Fabbricatore
      June 18th 2025
      Article

      The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
      March 4th 2025
      Podcast

      The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

      Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

      Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

      Gina Mauro
      June 11th 2025
      Article

      Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

      A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

      Machine Learning Approach May Predict Outcomes in RCC

      Kristie L. Kahl
      June 4th 2025
      Article

      A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.